Analysis
Use of randomised trials to decide when to monitor response to new treatment
BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39476.623611.25 (Published 14 February 2008) Cite this as: BMJ 2008;336:361
Data supplement
Appendix
Appendix
Files in this Data Supplement:
- Appendix - Appendix
Related articles
- Research Published: 24 June 2009; BMJ 338 doi:10.1136/bmj.b2266
- Clinical Review Published: 17 March 2005; BMJ 330 doi:10.1136/bmj.330.7492.644
- Research Published: 21 January 2011; BMJ 342 doi:10.1136/bmj.d12
- Editorial Published: 19 August 2010; BMJ 341 doi:10.1136/bmj.c4102
See more
- Prescribing parkrun: medicalising a walk in the parkBMJ April 08, 2025, 389 r670; DOI: https://doi.org/10.1136/bmj.r670
- GPs can prescribe tirzepatide to priority patient groups from JuneBMJ April 02, 2025, 389 r665; DOI: https://doi.org/10.1136/bmj.r665
- Exercise referral rates for patients with risk of cardiovascular disease vary widely across England, study reportsBMJ February 12, 2025, 388 r287; DOI: https://doi.org/10.1136/bmj.r287
- Cardiovascular disease: Just one in 12 eligible people had health check last year, watchdog findsBMJ November 13, 2024, 387 q2518; DOI: https://doi.org/10.1136/bmj.q2518
- Semaglutide’s CVD indication could cost US Medicare $145bn extra a yearBMJ August 28, 2024, 386 q1878; DOI: https://doi.org/10.1136/bmj.q1878
Cited by...
- Patterns and trends of potentially inappropriate high-density lipoprotein cholesterol testing in Australian adults at high risk of cardiovascular disease from 2008 to 2014: analysis of linked individual patient data from the Australian Medicare Benefits Schedule and Pharmaceutical Benefits Scheme
- Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data
- Monitoring Adherence to Medication by Measuring Change in Blood Pressure
- Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens: An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials
- How long should treatments be continued?
- Criteria for Scientific Evaluation of Novel Markers: A Perspective
- Lipid re-screening: what is the best measure and interval?
- Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data